Physician profile
James Newman
NPI 1619012762
$15,915.70
in general payments reported to CMS, 2019-2025
10 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $541 · 2021: $5,728 · 2022: $994 · 2023: $5,132 · 2024: $2,346 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,410 · Food and Beverage: $2,207 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,410.00 |
| Food and Beverage | $2,207.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $962.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,688.19 | 2023-2025 | |
| Allergan, INC. | $4,091.19 | 2019-2022 | |
| Merz North America, INC. | $3,457.30 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $1,357.42 | 2019-2024 | Dysport |
| Revance Therapeutics, INC. | $210.51 | 2024 | Daxxify |
| Polarityte, INC. | $50.00 | 2021 | |
| Baxter Healthcare | $33.52 | 2022 | |
| Trevena, INC. | $27.57 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,022,991.03 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.